Reported 4 days ago
As 2024 concludes, the weight-loss market is facing challenges with cautious outlooks for 2025. Results from Novo Nordisk's GLP-1 candidate CagriSema were less impressive than expected, and Amgen's MariTide poses questions about competition and market saturation. Analysts have downgraded their projections for both companies amid supply constraints. Eli Lilly's Zepbound and Mounjaro remain strong, but market dynamics may shift as new competitors emerge and copycat drugs face regulatory scrutiny.
Source: YAHOO